Abstract 5315: Anti-tumor activity of KRASG12C inhibitors is enhanced when combined with Cdc42 effector p21-activated kinase 4 targeting agents
Husain Yar Khan(Wayne State University), Asfar S. Azmi(The Barbara Ann Karmanos Cancer Institute), Ramzi M. Mohammad(The Barbara Ann Karmanos Cancer Institute), Sahar F. Bannoura(The Barbara Ann Karmanos Cancer Institute), Hirva Mamdani(Wayne State University), Amro Aboukameel(The Barbara Ann Karmanos Cancer Institute), William Senapedis(Karyopharm Therapeutics (United States)), Yosef Landesman(Karyopharm Therapeutics (United States)), Misako Nagasaka(University of California, Irvine), Erkan Baloglu(ProterixBio (United States)), Anthony F. Shields(Wayne State University), Yousef Mzannar(The Barbara Ann Karmanos Cancer Institute), Ibrahim Azar(Wayne State University), Steve Kim(The Barbara Ann Karmanos Cancer Institute), Yue Zhang(Southern Medical University), Ammar Sukari(The Barbara Ann Karmanos Cancer Institute), Yiwei Li(Ningxia Medical University), Rafic Beydoun(The Barbara Ann Karmanos Cancer Institute)
Cited by 0
Related Papers
Recommendations on the Use of <sup>18</sup>F-FDG PET in Oncology
|Journal of Nuclear Medicine|2008|1.1k
Erythrocyte–Platelet Hybrid Membrane Coating for Enhanced Nanoparticle Functionalization
|Advanced Materials|2017|756
Pembrolizumab for Platinum- and Cetuximab-Refractory Head and Neck Cancer: Results From a Single-Arm, Phase II Study
|Journal of Clinical Oncology|2017|653
Immunotherapy in Lung Cancer: Current Landscape and Future Directions
|Frontiers in Immunology|2022|373